Head to Head Comparison: Talphera (NASDAQ:TLPH) versus Acusphere (OTCMKTS:ACUS)

Talphera (NASDAQ:TLPH) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Insider and Institutional Ownership

37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 4.6% of Acusphere shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Talphera has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -1.2, indicating that its stock price is 220% less volatile than the S&P 500.

Profitability

This table compares Talphera and Acusphere’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-118.61%	-62.47%
Acusphere	N/A	N/A	N/A

Earnings and Valuation

This table compares Talphera and Acusphere”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30,000.00	1,548.35	-$14.29 million	($0.37)	-2.42
Acusphere	N/A	N/A	N/A	N/A	N/A

Acusphere has lower revenue, but higher earnings than Talphera.

Analyst Ratings

This is a summary of current recommendations for Talphera and Acusphere, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	0	1	0	2.00
Acusphere	0	0	0	0	0.00

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 235.20%. Given Talphera’s stronger consensus rating and higher possible upside, equities analysts plainly believe Talphera is more favorable than Acusphere.

Summary

Talphera beats Acusphere on 6 of the 9 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.